EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Artificial Intelligence Applications in Sickle Cell Retinopathy Imaging: Current Progress, Challenges, and Future Directions

Parim Shah, Hamza Ahmed Farah, Daniel J. Wisotsky, Paarth Nawani, Katherine Kovrizhkin, Eric R. Muir, Umar Mian, Tim Q. Duong

Journal of Ophthalmology · 2026-01 · 2026 (1)

DOI: 10.1155/joph/5579203 ↗
AbstractBibliografische Angaben

Abstract

Introduction Sickle cell retinopathy (SCR) is a leading cause of vision loss in patients with sickle cell disease, but its detection and monitoring remain difficult due to heterogeneous retinal microvascular changes and reliance on expert interpretation. Artificial intelligence has shown success in retinal disease detection, classification, and staging on retinal images, achieving expert‐level performance. This review summarizes recent artificial intelligence progress in SCR imaging and highlights future opportunities for clinical translation. Materials and Methods This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. A comprehensive literature search was performed in PubMed/MEDLINE, Embase, and Web of Science. Results A comprehensive PubMed search returned 15 records. After removal of duplicates and screening of titles and abstracts, 7 full‐text articles were assessed for eligibility. Of these, 4 studies met inclusion criteria and were included in the final review. Three full text articles were assessed for eligibility and inclusion from non‐PubMed sources. Two studies applied classical machine learning on features extracted from imaging data to classify SCR. Four studies used deep‐learning algorithms to detect SCR features on ophthalmological images. One study applied deep learning algorithms to classify SCR from other retinal diseases. Conclusions Deep learning has the potential to improve detection, stage, and monitor sickle cell retinopathy across multiple ophthalmological imaging methods. Additional research is needed to support clinical adoption. With continued development, AI‐based tools could enhance diagnostic precision, enable personalized care, and ultimately improve outcomes for patients with sickle cell retinopathy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →